. Author manuscript; available in PMC: 2012 Dec 1.

Published in final edited form as: J Virol Methods. 2011 Sep 17;178(1-2):143–152. doi: 10.1016/j.jviromet.2011.09.004

Table 3.

Analyzing ROCs of recombinant viral protein (R (VTI)) and viral lysate (VL (UCD)) based MMIAs

	R (VTI)			VL(UCD)			Comparison AUC between R (VTI) and VL(UCD)

	AUC	SE	95% CI	AUC	SE	95% CI	Difference	SE	95% CI	Significance level
B virus	0.984	0.00619	0.961 to 0.995	0.999	0.000872	0.984 to 1.000	0.0143	0.00592	0.00272 to 0.0259	p = 0.0155
SIV	0.975	0.0222	0.949 to 0.990	0.965	0.0185	0.937 to 0.984	0.00938	0.0168	−0.0236 to 0.0423	p = 0.5768
STLV-1	0.968	0.0189	0.940 to 0.985	0.964	0.0149	0.935 to 0.983	0.00395	0.0157	−0.0267 to 0.0346	p= 0.8008
SFV-1	0.992	0.0049	0.973 to 0.999	0.991	0.00737	0.972 to 0.999	0.000516	0.00468	−0.00866 to 0.00970	p = 0.9124
SRV	0.9	0.0239	0.859 to 0.933	0.894	0.0217	0.852 to 0.928	0.00579	0.0226	−0.0385 to 0.0500	p= 0.7976

ROC curve: receiver operating characteristic curve; AUC: area under ROC curve; SE: Standard Error; 95% CI: 95% Confidence Interval; VTI: MMIAs using recombinant virus proteins from Vaccine Technology Inc. (VTI); UCD: MMIAs using virus lysate preparation from University of California, Davis Clinical Proteomics Core Laboratory (UCD);